| Name | Title | Contact Details |
|---|
ENCOMPASS was established in 1985 as a wholly owned for profit subsidiary of the Iowa Foundation for Medical Care (IFMC). IFMC was established in 1972 through the cooperative efforts of business and physicians in response to increasing demands for
Clinomed Inc is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ambulatory Anethesia Associates Of Montgomery Pc is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diplomat is the nation`s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. We build solutions for today`s issues while laying the groundwork for tomorrow`s healthcare. Rooted in specialty pharmacy, our brands harness innovation to create a healthier world. These include: • Diplomat Specialty Infusion Group: Our specialty infusion services deliver treatments nationwide, but a high-touch approach makes our care personal. • Diplomat Specialty Pharmacy: We help patients across the country face complex and often rare conditions. • CastiaRx: The industry`s leading specialty benefit manager, combining full-service pharmacy benefit manager capabilities with deep specialty expertise. • EnvoyHealth: Firewalled from other Diplomat business, EnvoyHealth is a full-service healthcare solutions company using innovation and technology to help partners improve lives. At Diplomat, we are more than 2,000 professionals working together nationwide to help patients realize health, happiness, and longer, fuller lives. We stand behind our employees with exceptional benefits, continuing education, and award-winning wellness programs. We want this to be the greatest place you`ve ever worked. And we believe it will be.
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.